Clinical trial · Interventional
89Zr-labeled NY009 PET Imaging in Patients
NCT05691855CI-TRIAL-00063336unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY009 PET Imaging in patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 89Zr-NY009 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 89Zr-NY009
- interventionNames
- Drug: 89Zr-NY009
Primary outcomes (1)
- measure
- Evaluation of tissue distribution of 89Zr-NY009
- timeFrame
- 7 days
- description
- Biodistribution of 89Zr-NY009 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 89Zr-PET scans will be reported.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients voluntarily signed informed consent; 2. Age 18-75, male or female; 3. Patients diagnosed with cancer confirmed by histopathology or cytology; 4. At least one measurable solid lesion has been examined according RECIST1.1 standard; 5. ECOG score 0\~2. Exclusion Criteria: 1. Recovery from major trauma (including surgery) within 4 weeks prior to study treatment; 2. Patients with systemic or locally severe infections, or other serious coexisting diseases; 3. Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; 4. Patients with autoimmune diseases, including rheumatoid arthritis; 5. Inadequate control of arrhythmias, including atrial fibrillation; 6. Uncontrolled hypertension; 7. Patients with allergies or allergies to any component of the imaging agent or antibody; 8. Patients who cannot undergo PET/CT imaging scan; 9. Syphilis, HBV, HCV, or HIV positive subjects; 10. Male and female subjects of reproductive age cannot take effective contraceptive measures; 11. Pregnant or lactating women; 12. Patients with a history of mental illness or related conditions; 13. Other subjects considered unsuitable by researchers.
References
Publications (0)
Data not yet available
No reference posted for this study.